Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Growth Paris  >  Carmat    ALCAR   FR0010907956

CARMAT

(ALCAR)
  Report
Real-time Quote. Real-time Euronext Growth Paris - 01/28 08:13:56 am
26.8 EUR   -5.47%
10:48aCARMAT : Back towards the lower end of the range
01/18CARMAT : 2021 Financial Calendar
BU
01/06EUROPE : European stocks jump on vaccine hopes, Democrats on cusp of Senate victory
RE
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Growth Paris
01/22/2021 01/25/2021 01/26/2021 01/27/2021 01/28/2021 Date
29.85(c) 28.8(c) 28.8(c) 28.35(c) 26.8 Last
62 613 45 568 47 854 23 775 72 930 Volume
-3.86% -3.52% 0.00% -1.56% -5.47% Change
More quotes
Financials
Sales 2020 0,32 M 0,39 M 0,39 M
Net income 2020 -41,8 M -50,6 M -50,6 M
Net Debt 2020 16,9 M 20,5 M 20,5 M
P/E ratio 2020 -8,32x
Yield 2020 -
Sales 2021 10,3 M 12,5 M 12,5 M
Net income 2021 -39,1 M -47,3 M -47,3 M
Net Debt 2021 57,2 M 69,2 M 69,2 M
P/E ratio 2021 -8,41x
Yield 2021 -
Capitalization 359 M 434 M 435 M
EV / Sales 2020 1 158x
EV / Sales 2021 40,4x
Nbr of Employees 108
Free-Float 41,4%
More Financials
Company
Carmat specializes in the development of a fully implantable orthotopic artificial heart, its electrical power supply system, and its telediagnostics system. The artificial heart is intended for patients with advanced cardiac insufficiency who are ineligible for a transplant and have exhausted all medication alternatives. 
More about the company
Notations Surperformance© of Carmat
Trading Rating : Investor Rating :
More Ratings
All news about CARMAT
01/18CARMAT : 2021 Financial Calendar
BU
01/06EUROPE : European stocks jump on vaccine hopes, Democrats on cusp of Senate vict..
RE
01/06European stocks jump on vaccine hopes, Democrats on cusp of Senate victory
RE
01/06CARMAT : Outlines Commercial and Development Plan for Its Total Artificial Heart
BU
2020CARMAT : Obtains CE Marking For Artificial Heart
MT
2020CARMAT : Receives the CE Marking for Its Total Artificial Heart
BU
2020CARMAT : Update on the US Early Feasibility Study
PU
2020CARMAT : Provides Update on the US Early Feasibility Study
BU
2020CARMAT : Obtains Non-Dilutive Financing of €10 Million Guaranteed by the French ..
BU
2020CARMAT : obtains ANSM approval to resume PIVOTAL study implants in France
PU
2020CARMAT : Obtains ANSM Approval to Resume PIVOTAL Study Implants in France
BU
2020GLOBAL MARKETS LIVE: Boeing, Airbus, KPN…
2020CARMAT : is granted €13 million in national innovation funding to conduct the EF..
PU
2020CARMAT : is granted €13 million in national innovation funding to conduct the EF..
BU
2020CORRECTING AND REPLACING : CARMAT Reports Its 2020 Half-year Results and Issues ..
BU
More news
News in other languages on CARMAT
01/18CARMAT : Agenda financier 2021
01/06Résumé des principales informations économiques du mercredi 6 janvier 2021
01/06CARMAT : un coeur bientôt à prendre
01/06EUROPE : Borse Europa In rialzo, bene bancari ed energetici in attesa risultati ..
01/06EN DIRECT DES MARCHES : Alstom, Rubis, Pixium, Carmat, X-Fab, Amazon, Tiffany, A..
More news
Stock Trading Strategies
CARMAT - 10:48
Back towards the lower end of the range
BUY
More Stock Trading Analysis
Chart CARMAT
Duration : Period :
Carmat Technical Analysis Chart | ALCAR | FR0010907956 | MarketScreener
Technical analysis trends CARMAT
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 41,81 €
Last Close Price 28,35 €
Spread / Highest target 108%
Spread / Average Target 47,5%
Spread / Lowest Target 6,70%
EPS Revisions
Managers and Directors
NameTitle
Stéphane Piat Chief Executive Officer & Director
Alain Carpentier Honorary President
Jean-Pierre Garnier Chairman
Pascale d’Arbonneau Chief Financial & Administrative Officer
Marc Grimmé Director-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
CARMAT0.18%434
STRYKER CORPORATION-5.83%86 714
SMITH & NEPHEW PLC6.82%19 348
INSPIRE MEDICAL SYSTEMS, INC.0.40%5 086
VENUS MEDTECH (HANGZHOU) INC.20.24%4 594
GLAUKOS CORPORATION17.42%3 971